Pfizer, Inc. Press Releases

PFE 
$33.26
*  
0.83
2.56%
Get PFE Alerts
*Delayed - data as of Aug. 27, 2015  -  Find a broker to begin trading PFE now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By



Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer
8/26/2015 7:30:00 AM - Business Wire
▲3.65 % Price Change since this news event. The Volume Ratio is 1.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alvogen to Acquire Product Portfolio from Pfizer for the U.S. Market
8/26/2015 6:12:00 AM - Business Wire
▲4.00 % Price Change since this news event. The Volume Ratio is 1.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
8/24/2015 8:15:00 AM - Business Wire
▲3.61 % Price Change since this news event. The Volume Ratio is 3.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition
8/24/2015 8:00:00 AM - Business Wire
▲3.29 % Price Change since this news event. The Volume Ratio is 3.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA® (Meningococcal Group B Vaccine)
8/21/2015 8:00:00 AM - Business Wire
▼-3.45 % Price Change since this news event. The Volume Ratio is 2.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer
8/20/2015 11:23:00 AM - Business Wire
▼-4.62 % Price Change since this news event. The Volume Ratio is 1.66.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Granted Approval From The Canadian Competition Bureau For Hospira Acquisition
8/14/2015 8:35:00 AM - Business Wire
▼-5.91 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Receives Approval from the Australian Competition and Consumer Commission for Pending Acquisition of Hospira
8/13/2015 8:15:00 AM - Business Wire
▼-6.05 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
8/10/2015 8:00:00 AM - PR Newswire
▼-5.30 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Receives Approval From European Commission For Pending Acquisition Of Hospira
8/4/2015 11:36:00 AM - Business Wire
▼-7.59 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
8/3/2015 8:30:00 AM - Business Wire
▼-7.61 % Price Change since this news event. The Volume Ratio is 0.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Hospira Reports Second-Quarter 2015 Results
7/29/2015 7:30:00 AM - PR Newswire


PFIZER REPORTS SECOND-QUARTER 2015 RESULTS
7/28/2015 7:00:00 AM - Business Wire
▼-4.94 % Price Change since this news event. The Volume Ratio is 4.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility
7/22/2015 8:30:00 AM - Business Wire
▼-5.08 % Price Change since this news event. The Volume Ratio is 1.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


America''s Most-Preferred Bone Health Brand Launches New Caltrate® Bone & Joint Health Supplement
7/21/2015 8:00:00 AM - Business Wire
▼-5.89 % Price Change since this news event. The Volume Ratio is 1.13.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Watch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax Laboratories
7/20/2015 9:25:00 AM - PR Newswire
▼-5.24 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer’s Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announce Collaboration to Help Advance Immunological Research
7/8/2015 8:30:00 AM - Business Wire
▼-0.92 % Price Change since this news event. The Volume Ratio is 0.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Nodality, Inc. Appoints Kathleen LaPorte as Chief Executive Officer
7/8/2015 8:00:00 AM - Business Wire
▼-0.92 % Price Change since this news event. The Volume Ratio is 0.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery
7/7/2015 8:00:00 AM - Business Wire
▼-0.42 % Price Change since this news event. The Volume Ratio is 1.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets
7/2/2015 4:30:00 PM - Business Wire
▼-0.33 % Price Change since this news event. The Volume Ratio is 1.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D
7/2/2015 9:30:00 AM - PR Newswire
▼-1.92 % Price Change since this news event. The Volume Ratio is 1.71.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Joseph J. Echevarria Elected To Pfizer’s Board Of Directors
6/25/2015 11:20:00 AM - Business Wire
▼-2.92 % Price Change since this news event. The Volume Ratio is 2.09.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day